MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual ...